Literature DB >> 3286334

Molecular mimicry between insulin and retroviral antigen p73. Development of cross-reactive autoantibodies in sera of NOD and C57BL/KsJ db/db mice.

D V Serreze1, E H Leiter, E L Kuff, P Jardieu, K Ishizaka.   

Abstract

Enzyme-linked immunosorbent assay (ELISA) was used to study temporal development of murine autoantibodies against insulin and both type C and intracisternal type A retroviral antigens. The nonobese diabetic (NOD) mouse, a model for autoimmune, insulin-dependent diabetes, was compared with a related, but diabetes-resistant, strain, nonobese normal (NON). Similarly, C57BL/KsJ db/db mice (insulin-resistant model of insulin-dependent diabetes and obesity) were compared with diabetes-resistant C57BL/6 db/db mice. NOD mice developed much higher autoantibody titers than did NON mice. Whereas type C autoantibodies in NOD developed to peak titer shortly after mice were weaned, autoantibodies against insulin and p73 (group-specific antigen of the intracisternal type A particle) did not develop until shortly before, or concomitant with, the development of hyperglycemia. Two NOD mice not developing hyperglycemia during the 40-wk study period were distinguished from the mice developing diabetes by a delayed onset of insulin (but not p73) autoantibodies. Our findings suggest that in NOD mice, the appearance of insulin and p73 autoantibodies signifies that extensive underlying necrosis of beta-cells occurred. C57BL/KsJ db/db mice (with extensive beta-cell necrosis and early hyperglycemia) developed much higher autoantibody titers to insulin and p73 than did the diabetes-resistant C57BL/6 db/db mice. However, the presence of autoantibodies in normoglycemic C57BL/KsJ +/db controls demonstrated that elevated autoantibody titers alone were insufficient to produce diabetes in this model. Absorption studies indicated that autoantibodies against p73 recognized a common epitope on insulin and IgE-binding factor. The potential significance of this molecular mimicry is discussed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3286334     DOI: 10.2337/diab.37.3.351

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  13 in total

1.  Beta cell expression of endogenous xenotropic retrovirus distinguishes diabetes-susceptible NOD/Lt from resistant NON/Lt mice.

Authors:  H R Gaskins; M Prochazka; K Hamaguchi; D V Serreze; E H Leiter
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

2.  Transplantation analysis of B cell destruction in (NOD x CBA)F1 mouse bone marrow chimeras.

Authors:  D V Serreze; E H Leiter; L D Shultz
Journal:  Diabetologia       Date:  1990-02       Impact factor: 10.122

3.  Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice.

Authors:  D G Karounos; J S Bryson; D A Cohen
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

Review 4.  Temporal discontinuities in progression of NOD autoimmune diabetes.

Authors:  G B Rudy; R M Sutherland; A M Lew
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

5.  Differences in intracisternal A-particle and GLN proviral loci suggest a genetic contribution from a DBA/2-like strain in generation of the C57BL/Ks strain.

Authors:  K K Lueders
Journal:  Mamm Genome       Date:  1995-02       Impact factor: 2.957

Review 6.  Autoantibodies in insulin-dependent diabetes mellitus.

Authors:  E Bosi; E Bonifacio
Journal:  J Endocrinol Invest       Date:  1994 Jul-Aug       Impact factor: 4.256

7.  Longitudinal study of islet cell antibodies and insulin autoantibodies and development of diabetes in non-obese diabetic (NOD) mice.

Authors:  S Reddy; N Bibby; R B Elliott
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

8.  Hyperglycemia-induced B cell toxicity. The fate of pancreatic islets transplanted into diabetic mice is dependent on their genetic background.

Authors:  O Korsgren; L Jansson; S Sandler; A Andersson
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

9.  Recognition of binding sites on Candida albicans by monoclonal antibodies to human leukocyte antigens.

Authors:  C L Mayer; R D Diamond; J E Edwards
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

10.  Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23).

Authors:  D Daniel; D R Wegmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.